Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
TEL AVIV, Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had filed a patent application under the Patent Cooperation Treaty (PCT) for novel formulations developed for treatment of various cancer types.
Said patent application includes ample preclinical supporting data collected from in-vitro experiments performed in the company's in-house drug discovery facilities in Israel, as well as from in-vivo experiments performed on mice.
Gabriel Yariv, Cannabics Pharmaceuticals President and COO: "After a rigorous process of screening, testing and analyzing a variety of unique molecular compounds, and their effect on human biopsies and cancer cell lines, we have identified specific formulations that stand out in terms of their performance. These formulations are detailed in the current PCT application, and we plan to turn them into new drug candidates for specific cancer treatments in the near future".
This news follows the company's announcement from last week concerning "Notice of Allowance" received by the company from The Mexican Patent and Trademark Office (IMPI) on a separate patent application.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed April 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
SOURCE Cannabics Pharmaceuticals Inc.
Company Codes: OTC-PINK:CNBX, OTC-QB:CNBX, OtherOTC:CNBX